Compound and Digenic Heterozygosity Contributes to Arrhythmogenic Right Ventricular Cardiomyopathy  by Xu, Tianhong et al.
F
c
H
¶
#
s
M
S
M
Journal of the American College of Cardiology Vol. 55, No. 6, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00
PCompound and Digenic Heterozygosity Contributes
to Arrhythmogenic Right Ventricular Cardiomyopathy
Tianhong Xu, PHD,* Zhao Yang, MD, PHD,†‡ Matteo Vatta, PHD,‡
Alessandra Rampazzo, MD, PHD,§ Giorgia Beffagna, PHD,‡§ Kalliopi Pillichou, PHD,§
Steven E. Scherer, PHD,* Jeffrey Saffitz, MD, PHD,# Joshua Kravitz, BS,‡ Wojciech Zareba, MD,**
Gian Antonio Danieli, PHD,§ Alessandra Lorenzon, PHD,§ Andrea Nava, MD,
Barbara Bauce, MD, PHD, Gaetano Thiene, MD,¶ Cristina Basso, MD, PHD,¶
Hugh Calkins, MD,†† Kathy Gear, RN,‡‡ Frank Marcus, MD,‡‡ Jeffrey A. Towbin, MD,§§
for the Multidisciplinary Study of Right Ventricular Dysplasia Investigators
Houston, Texas; Padua, Italy; Boston, Massachusetts; Rochester, New York; Baltimore, Maryland;
Tucson, Arizona; and Cincinnati, Ohio
Objectives The aim of this study was to define the genetic basis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
Background Arrhythmogenic right ventricular cardiomyopathy, characterized by right ventricular fibrofatty replacement and
arrhythmias, causes sudden death. Autosomal dominant inheritance, reduced penetrance, and 7 desmosome-
encoding causative genes are known. The basis of low penetrance is poorly understood.
Methods Arrhythmogenic right ventricular cardiomyopathy probands and family members were enrolled, blood was ob-
tained, lymphoblastoid cell lines were immortalized, deoxyribonucleic acid was extracted, polymerase chain re-
action (PCR) amplification of desmosome-encoding genes was performed, PCR products were sequenced, and
diseased tissue samples were studied for intercellular junction protein distribution with confocal immunofluores-
cence microscopy and antibodies against key proteins.
Results We identified 21 variants in plakophilin-2 (PKP2) in 38 of 198 probands (19%), including missense, nonsense,
splice site, and deletion/insertion mutations. Pedigrees showed wide intra-familial variability (severe early-onset
disease to asymptomatic individuals). In 9 of 38 probands, PKP2 variants were identified that were encoded in
trans (compound heterozygosity). The 38 probands hosting PKP2 variants were screened for other desmosomal
genes mutations; second variants (digenic heterozygosity) were identified in 16 of 38 subjects with PKP2 vari-
ants (42%), including desmoplakin (DSP) (n  6), desmoglein-2 (DSG2) (n  5), plakophilin-4 (PKP4) (n  1),
and desmocollin-2 (DSC2) (n  1). Heterozygous mutations in non-PKP 2 desmosomal genes occurred in 14 of
198 subjects (7%), including DSP (n  4), DSG2 (n  5), DSC2 (n  3), and junctional plakoglobin (JUP) (n  2).
All variants occurred in conserved regions; none was identified in 700 ethnic-matched control subjects. Immuno-
histochemical analysis demonstrated abnormalities of protein architecture.
Conclusions These data suggest that the genetic basis of ARVC includes reduced penetrance with compound and digenic het-
erozygosity. Disturbed junctional cytoarchitecture in subjects with desmosomal mutations confirms that ARVC is
a disease of the desmosome and cell junction. (J Am Coll Cardiol 2010;55:587–97) © 2010 by the American
College of Cardiology Foundation
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cardiomyopathy/dysplasia (ARVC)
has been defined as a primary right
ventricular (RV) cardiomyopathy
initially described by Marcus et al.
(1) in the early 1980s. It is charac-
terized by fibrofatty infiltration
of the RV myocardium and clin-
ically presents with ventricular
arrhythmias, heart failure, syn-
cope, and sudden death (1,2).
The left ventricle (LV) might
also be affected (3). In familial
cases of ARVC, autosomal dom-
inant inheritance with reduced
penetrance has been reported
and is believed to account for
approximately 30% of cases (4).
In the remaining sporadic cases,
the etiology might be an acquired
cause such as myocarditis (5,6) or
n unidentified inherited disorder. To date, multiple genetic
oci and 7 genes—including desmoplakin (DSP) (7),
lakophilin-2 (PKP2) (8), desmoglein-2 (DSG2) (9),
esmocollin-2 (DSC2) (10), transforming growth factor 3
TGF 3) (11), ryanodine receptor 2 (RYR2) (12), and
ransmembrane protein-43 (TMEM43) (13)—have been
dentified in ARVC patients. In addition, 2 complex car-
iocutaneous disorders with autosomal recessive inheritance
n which cardiomyopathy is associated with woolly hair and
almoplantar keratoderma have been reported. These in-
lude Naxos disease with ARVC (14) and Carvajal syn-
rome associated with an LV cardiomyopathy (15). The
enes identified for these disorders include homozygous
utations in junctional plakoglobin (JUP) in Naxos disease
16) as well as homozygous mutations in DSP in Carvajal
yndrome (17). The most common gene variant identified
n ARVC is PKP2, initially reported by Gerull et al. (8) to
e mutated in approximately 25% of patients with autoso-
al dominant inherited disease. In the analysis of PKP2, an
ssential armadillo-repeat protein of the cardiac desmo-
ome, they identified heterozygous mutations in 32 of 120
nrelated individuals with ARVC (8). Other investigations
ave confirmed these findings (18–21). Of genes identified
o date causing ARVC, a majority encode desmosomal
roteins. Within cardiomyocytes, 2 types of cell adhesion
unctions are responsible for intercellular adhesion: the
ondazione Cassa di Risparmio, Padova e Rovigo. Dr. Towbin was funded by the
ational Heart, Lung, and Blood Institute of the National Institutes of Health grant
R01 HL087000 (PCSR), the Texas Children’s Foundation Chair in Pediatric
olecular Cardiology Research, The Vivian L. Smith Foundation, The Abby Glaser
oundation, the Children’s Cardiomyopathy Foundation, the Baylor College of
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Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
DNA  deoxyribonucleic
acid
DSC  desmocollin
DSG  desmoglein
DSP  desmoplakin
LV  left
ventricle/ventricular
MRI  magnetic resonance
imaging
PCR  polymerase chain
reaction
PKP  plakophilin
RV  right
ventricle/ventriculare
Manuscript received November 22, 2008; revised manuscript received October 13,
009, accepted November 10, 2009.esmosomes and fascia adherens junctions (22). These cell
dhesion junctions are both located at the cardiomyocyte
ntercalated disk, and both contain intracellular proteins
hat link the cytoplasmic domains of cadherins to compo-
ents of the cytoskeleton. In cardiomyocytes, a variety of
roteins interact to form functional cell–cell junctions. The
SGs and DSCs are connected to the desmin cytoskeleton
y DSP, JUP (-catenin), and PKP2. These latter proteins,
UP and PKP2, are members of the armadillo family of
uclear and junctional proteins (23,24). The PKP-2 inter-
cts with DSP, DSG, and intermediate filament proteins at
ites within its N-terminus. The DSP and PKP2 are located
nly in desmosomes, whereas JUP participates as a linker in
oth desmosomes and adherens junctions. The adherens
unctions are located at the ends of sarcomeres and are
inked to sarcomeric actin through intracellular linker pro-
eins, most notably members of the catenin family, includ-
ng JUP, -catenin, -catenin, and p120 catenin.
In this study, we analyzed probands and family members
or ARVC with a standardized clinical protocol either
eveloped as part of the North American ARVD Registry
25) or with the standard Task Force criteria (Table 1) (26).
ll individuals were screened for mutations in all of genes
ncoding proteins involved in desmosomal function, even if
variant were already identified in any of these desmosome-
ncoding genes. We report identification of multiple muta-
ions in these genes, including autosomal dominant het-
rozygous mutations in 26% of subjects (52 of 198),
ncluding 38 in PKP2 and 14 in other desmosome-encoding
enes.
Additionally, compound heterozygous mutations and di-
enic mutations were identified in 42% of the subjects (16 of
8) in whom PKP2 mutations were identified. In addition,
e demonstrate that many PKP2 mutations have low
enetrance and in many cases might not be the primary
ause of the disease, contradicting the previously reported
ontention that PKP2 is the major ARVC-causing gene,
ccounting for the cause of disease in 25% of ARVC
atients.
ethods
atient evaluation. After informed consent, probands
ere evaluated by noninvasive and invasive studies, includ-
ng physical examination and history/family history, chest
adiography, 12-lead electrocardiogram, echocardiography,
nd cardiac magnetic resonance imaging (MRI).
In most cases, the clinical evaluation followed the proto-
ol of the National Institutes of Health–funded North
merican ARVD Registry (25), which included invasive
tudies including cardiac catheterization, ventricular angiog-
aphy, and endomyocardial biopsy. In these subjects, all
tudies (noninvasive and invasive testing) were analyzed by
ore laboratories. Family members were evaluated with the
oninvasive studies only (electrocardiogram, cardiac MRI,
chocardiogram, chest X-ray, and physical examination
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February 9, 2010:587–97 Compound and Digenic Heterozygosity in ARVCith history/family history). In the subjects in whom
enetic studies were performed but who declined enroll-
ent in the Registry or international subjects not eligible to
nroll in the Registry, the Task Force diagnostic criteria
Table 1) were used (26). Diagnostic criteria previously
escribed by McKenna et al. (26) were used to determine
ffectation status. After informed consent, blood for de-
xyribonucleic acid (DNA) extraction and lymphoblastoid
ell line immortalization was obtained, as approved by the
aylor College of Medicine Institutional Review Board.
NA sequencing analysis. Genomic DNA samples of the
43 U.S. and 55 Italian ARVC index cases (n  198) were
btained from blood samples and immortalized lympho-
lastoid cell lines as previously described (27) and amplified
y polymerase chain reaction (PCR) with primers designed
o amplify the coding exons of desmosome-encoding genes
KP2, DSP, JUP, DSC2, DSG2, and plakophilin-4 (PKP4),
nd the intermediate filament-encoding gene desmin (DES).
ask Force Diagnostic Criteria for ARVCTable 1 Task Force Diagnostic Criteria for ARVC
I. Global and/or regional dysfunction and structural alterations
Major
Severe dilation and reduction of RV ejection fraction with no (or only mild)
LV impairment
Localized RV aneurysms (akinetic or dyskinetic areas with diastolic bulging)
Severe segmental dilation of the RV
Minor
Mild global RV dilation and/or ejection fraction reduction with normal LV
Mild segmental dilation of the RV
Regional RV hypokinesia
II. Tissue characterization of wall
Major
Fibrofatty replacement of myocardium on endomyocardial biopsy
III. Repolarization abnormalities
Minor
Inverted T waves in right precordial leads (V2 and V3) in people
age 12 yrs, in absence of right bundle-branch block
IV. Depolarization/conduction abnormalities
Major
Epsilon waves or localized prolongation (110 ms) of the QRS complex in
right precordial leads (V1–V3)
Minor
Late potentials (signal-averaged ECG)
V. Arrhythmias
Minor
Left bundle-branch block type ventricular tachycardia (sustained and
nonsustained) by ECG, Holter, or exercise testing
Frequent ventricular extrasystoles (1,000/24 h) (Holter)
VI. Family history
Major
Familial disease confirmed at necropsy or surgery
Minor
Family history of premature sudden death (35 yrs) due to suspected
RV dysplasia
amilial history (clinical diagnosis based on present criteria). Data adapted from McKenna et al.
26). The diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) is fulfilled by the
resence of 2 major, 1 major plus 2 minor, or 4 minor criteria from I to VI (25,26).
ECG  electrocardiogram; LV  left ventricle/ventricular; RV  right ventricle/ventricular.ther nondesmosomal genes were excluded from this anal- psis. The PCR products from the U.S. cohort were se-
uenced with Big Dye Terminator version 3.1 chemistry
Applied Biosystems, Foster City, California) and analyzed
ith an ABI 3730 DNA sequencer (Applied Biosystems).
n addition, the 55 Italian ARVC index cases were screened
or mutations by denaturing high-performance liquid chro-
atography and direct sequencing. Denaturing high-
erformance liquid chromatography analysis was performed
ith the use of WAVE Nucleic Acid Fragment Analysis
ystem 3500HT with DNASep HT cartridge (Trans-
enomic, Ltd., Omaha, Nebraska). Temperatures for sam-
le analysis were selected with the use of WaveMaker
oftware version 4.0 (San Francisco, California). In all 198
ubjects, therefore, we analyzed the entire coding sequence
nd the surrounding intronic sequences of DES and of the
esmosomal genes including PKP2, DSP, DSC2, DSG2,
UP, DSC2, DSG2, and PKP4.
loning and sequencing of PKP2 complementaryDNA. To-
al ribonucleic acid was isolated from lymphoblastoid cell lines
ith an RNeasy Mini Kit (Qiagen, Stanford, California) and
ubjected to random hexamer-primed complementary DNA
ynthesis with Superscript II (Invitrogen, Carlsbad, Califor-
ia). The PKP2 complementary DNA was amplified by PCR
ith oligonucleotides specific for the complementary DNA
equence of PKP2 (5=-CCAGCTGAGTACGGCTA-
ATC-3=; 5=-TCAGTCTTTAAGGGAGTGGT-3=),
loned into TA-vectors (Topo TA Cloning Kit, Invitrogen)
nd then introduced into TOP10 cells with a One Shot
hemical Transformation kit (Invitrogen). For each patient
ample, plasmid DNA was isolated and the insert was se-
uenced with the same oligonucleotides.
mmunohistochemistry. When available, formalin-fixed or
nap-frozen cardiac tissues from affected patients were studied
or the distribution of intercellular junction proteins with
onfocal immunofluorescence microscopy, as previously de-
cribed (28,29). Antigens were exposed in paraffin-embedded
ections with microwave antigen-recovery techniques (28,29)
nd then stained with commercial rabbit polyclonal antibodies
gainst connexin 43 (Cx43) (Zymed, Invitrogen), the
-terminal domain of DSP (Serotec, Raleigh, North Caro-
ina), a conserved sequence in the N-cadherins (Sigma-
ldrich, St. Louis, Missouri), and DES (ScyTek Laboratories,
ogan, Utah) as well as mouse monoclonal antibodies against
UP (Sigma-Aldrich), DSC 2/3 (Zymed, Invitrogen), PKP-2
Biodesign International, Saco, Maine), -catenin (Zymed,
nvitrogen), -catenin (Zymed, Invitrogen), and the
-terminus of JUP (Research Diagnostics, Inc., Concord,
aine). The sections were then stained with appropriate
econdary antibodies conjugated with CY3 and visualized by
onfocal microscopy as described previously (28,29). Patient
amples were stained simultaneously with myocardial sections
repared from 3 age-matched control subjects with no clinical
r autopsy evidence of heart disease. The amount of immuno-
eactive signal for each protein at the intercalated disks was
valuated in a blinded fashion and scored as being strongly
resent, weakly present, or absent.
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enetic analysis: PKP2 mutations and compound het-
rozygosity. After informed consent, 198 probands (143
orth American, 55 Italian) meeting clinical criteria for the
iagnosis of ARVC with the Task Force criteria (Table 1)
nd/or ARVD registry criteria were enrolled in the genetic
nalysis study. All subjects were screened for mutations in
ll desmosome-encoding genes, with complete sequencing
f the entire gene performed in all cases. Twenty-one
ariants in PKP2 were identified in 38 of the 198 probands
19%), a frequency similar to previous reports (8,18–21).
he variants identified included 8 missense, 4 nonsense,
splice site mutations, and 8 deletion/insertion mutations;
he deletion/insertion variants each predict a protein frame
hift (Table 2). Several variants were identified in multiple
robands, including nonsense and frame-shift variants
Table 2). All of the missense substitutions resulted in
hanges at residues that are conserved between species
Supplementary Fig. 1). Among the variants identified, the
plice site substitution detected in intron 10 and the
509delA in exon 13 have been previously reported (8). The
emaining variants are novel. Despite the fact that several of
hese variants were identified in multiple individuals, anal-
sis of 700 ethnically matched control individuals (1,400
hromosomes) identified only 1 of these variants (A372P) in
he control population (1 in 700).
Analysis of the family pedigrees shows that there is
ignificantly reduced penetrance of these PKP2 variants,
imilar to that reported by Gerull et al. (8) (Figs. 1A and
B). However, in 9 of the probands with PKP2 variants,
e identified 2 distinct PKP2 variants (Table 3, Patients
PKP2 Gene Variants Identified in Patients WithTable 2 PKP2 Gene Variants Identified in Pa
Nucleotide Change Exon Amino
145_148delCAGA 1 S50
419CT 3 S14
627CG 3 S20
630CT 3 Q2
1114GC 4 A37
1162CT 4 R3
1170-2AG Intr
1212insT 5 L40
1368delA 5 K4
1592TG 7 I53
1613GA 7 W5
1643delG 7 G5
1760GA 8 V58
1978CT 10 Q6
2009delC 10 N6
2119CT 10 Q7
2146-1GC Intr
2197_2202insGdelCACACC 11 H7
2359CT 12 L78
2447_2448delCC 12 T81
2509delA 13 V83ARVC  arrhythmogenic right ventricular cardiomyopathy; PKP2  plakophil5, #7, #8, #11, #12, #14, #15, #16, and #17), consistent
ith compound heterozygosity. One of these probands
Patient #5 in Table 3, Fig. 1C) was a member of a family
ith a history of ARVC in his generation (Fig. 1C). The
NA was available from the living affected subject
Patient #6 in Table 3, Fig. 1C) and unaffected siblings of
he proband as well as the phenotypically normal parents,
aternal uncle, and paternal grandparents. All family
embers were clinically evaluated with the Task Force
riteria (Table 1). Only the clinically affected brother
arried both variants (Fig. 1C). The parents were carriers
f individual PKP2 variants, and the clinically unaffected
not meeting Task Force criteria) sibling hosted only the
ariant transmitted by his father and paternal grandfather
Fig. 1C). Reverse transcription PCR of PKP2 messenger
ibonucleic acid was performed with samples obtained
rom 5 other affected probands, and sequencing revealed
hat in each case the variants were encoded in trans.
hus, these variants were either inherited independently
rom the phenotypically normal patients or were de novo.
s noted in Table 3, disparities between the clinical
henotypes and genetic findings seem somewhat com-
on. Notably, all subjects had RV involvement, several
ad biventricular disease, and all had associated arrhyth-
ias. Importantly, not all subjects met full Task Force
riteria, thereby pointing to imperfections in these crite-
ia and necessitating modifications of these criteria (Mar-
us et al. [30]).
These findings led us to consider the possibility that
RVC might be due to another form of “compound
eterozygosity” with mutations/genetic variants in 2 desmo-
s With ARVC
hange U.S. Probands Italian Probands
0 4 3
1 0
0 1
1 1
3 0
1 0
1 0
09 1 0
58 1 0
3 0
2 0
62 0 1
0 1
1 0
83 0 1
0 1
3 0
40 1 0
1 0
25 0 2
30 3 0ARVCtient
Acid C
fsX11
0F
9R
11X
2P
88W
on 4
4fsX4
56fsX4
1S
38X
48fsX5
7I
60X
70fsX6
07X
on 10
33fsX7
7F
6fsX8
7fsX9in-2.
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February 9, 2010:587–97 Compound and Digenic Heterozygosity in ARVComal protein encoding genes required for clinical disease,
alled “digenic heterozygosity.”
enetic analysis: digenic heterozygosity. In all 198 pro-
ands, the desmosome-encoding genes DSP, DSC2, DSG2,
UP, DSC2, DSG2, PKP4, and DES were sequenced in
ddition to PKP2 sequencing. This sequencing identified 13
ariants in second desmosomal genes in 13 subjects with
KP2 variants, including DSP in 6 cases, DSG2 in 5 cases,
KP4 in 1 subject, and DSC2 in 1 subject (Table 3). None
f these variants was identified in at least 700 ethnic-
atched control subjects (1,400 chromosomes). Thus, of
he 38 probands with PKP2 variants, compound or digenic
eterozygosity was identified in 16 (42%), including 6
robands with 3 variants: in 2 of these cases, 1 of the PKP2
ariants was the A372P polymorphism identified in the
Figure 1 Pedigrees of 3 Families With
PKP2 Variants and Incomplete Penetrance
(A) L404fsX409 plakophilin-2 (PKP2) was identified in the proband and unaf-
fected sister and was inherited from the unaffected mother (). In addition, a
de novo variant, desmoplakin (DSP) Q90R, was identified in the proband (dia-
mond). The arrow indicates the proband. (B) K456NfsX458 was identified in
the proband and inherited from the unaffected mother (). The arrow indi-
cates the proband. (C) Pedigree of a family with compound heterozygous PKP2
variants. V837fsX930 () was identified in the proband and both of his sib-
lings and was inherited from the unaffected father, who in turn inherited it from
his unaffected father. R388W (diamonds) was identified in the proband and
his affected brother and was inherited from his phenotypically normal mother.
The arrow indicates the proband. NA  not available for genetic analysis; yo 
years old.ontrol population. Five probands had additional family cembers available for clinical and genetic evaluation, in-
luding the following probands: patient 1 with the Q90R
SP variant (Table 3), the DSP W207X variant (Patient #2
n Table 3), the DSG2 V56M variant (Patient #14 in Table 3),
he DSG2 R146H variant (Patient #15 in Table 3), and the
SP R1255K variant (Patient #16 in Table 3). The DSP
90R variant was a de novo substitution and therefore
ould be pathogenic alone or in combination with the PKP2
ariant (Fig. 1A). In Patient #12, a 4609CT DSP substi-
ution (R1537C) was also identified, a variant previously
eported as a single nucleotide polymorphism. Whether this
ariant becomes clinically relevant in combination with the
KP2 variants and is needed for the development of clinical
eatures is speculation until animal models are completed. In
he family of Patient #2 (Fig. 2A), the PKP2 I531S variant
as identified in 3 of the 4 siblings available for study. All
amily members were clinically evaluated with the Task
orce criteria (Table 1), and 1 of the 3 siblings was clinically
naffected (and also has twin carrier daughters), whereas the
ther 2 siblings were clinically affected. Only the proband
osted the second variant, DSP W207X. In this case, we
ropose 3 potential interpretations of these data. Because
he proband had the most severe phenotype (sudden death
t age 25 years and severe ARVC on autopsy), it is possible
hat the DSP W207X mutation was required to manifest
evere clinical disease. Second, this mutation might have no
nvolvement in the development of disease and another as
et identified mutation is carried by the affected siblings but
ot by the unaffected sibling. Third, the I531S mutation
ight be disease-causing alone with extremely reduced
enetrance, as has been described in other forms of cardio-
yopathy, and requires other factors—such as acquired
gents—to manifest and contribute to clinical expression. In
his regard, it should be noted that the proband developed
ononucleosis 2 years before death.
Patient #14 hosted a DSG2 V56M variant, as previously
oted; in addition, however, this subject also had 2 addi-
ional PKP2 variants (Fig. 2B). On the basis of evaluation of
he pedigree, it is difficult to be certain as to the role of each
f these variants; however, it seems that the combination of
KP2 S140F and DSG2 V56M, which was only detected in
he proband, led to a more severe clinical phenotype (Fig.
B).
Patient #15, a 51-year-old man, was diagnosed with a
evere form of ARVC at the age of 39 years after an episode
f ventricular fibrillation. He was found to host 3 different
ariants (PKP2 S209R, PKP2 T816fsX825, and DSG2
146H) (Fig. 3A). The PKP2 T816fsX825 was inherited
rom his mother (II,2). Because his father’s DNA was not
vailable, it was not possible to establish whether the 2
issense variations (PKP2 S209R and DSG2 R146H) were
nherited from the father or are de novo mutations. His
other and maternal aunt, who both carried the PKP2
rame-shift variant, were clinically unaffected by Task Force
riteria and were asymptomatic.
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Compound and Digenic Heterozygosity in ARVC February 9, 2010:587–97Patient #16, a 40-year-old man, was diagnosed with a
evere form of ARVC after an episode of ventricular
brillation that occurred during a sports activity. After
esuscitation, he received an implantable cardioverter-
efibrillator. His family history included a male cousin who
ied suddenly at 30 years of age while hiking. No autopsy
as performed. The proband (II,1) inherited the DSP
issense mutation and PKP2 stop mutation from his
other (I,2) and the missense PKP2 mutation from the
ather (I,1) (Fig. 3B). At least 1 mutation was also detected
n the proband’s sons. In this family, all mutation carriers,
ith the exception of the proband, were completely asymp-
omatic and clinically unaffected by Task Force criteria.
Overall, there was more ventricular fibrillation and
xercise-induced ventricular tachycardia in those subjects
aving compound or digenic heterozygosity compared with
hose subjects with single heterozygous PKP2 mutations. In
ddition, the age of onset of symptomatic ARVC, most
ommonly ventricular arrhythmias or syncope, was earlier
n those subjects with multiple genetic variants in PKP2
r in PKP2 plus other desmosomal genes (mean age 31.5
ears) compared with those subjects with single heterozy-
ous gene mutations (mean age 39.5 years). Therefore, it
eems that compound and digenic heterozygosity leads to
ore clinically apparent and severe ARVC with an earlier
ge of onset than those hosting heterozygous mutations
n these genes.
enetic analysis: single gene mutations. In 14 of the 198
ubjects analyzed (7%), single heterozygous mutations were
linical Demographic Data of ARVC Subjects With Desmosomal GeTable 3 Clinical Demographic Data of ARVC Subjects With Des
Patient # Sex
Age Onset
(yrs) FHX
Affected
Parents Nationality P
1 F 25 N No U.S.
2 F 22 Y No U.S.
3 F 23 Y No U.S.
4 M 29 N No U.S.
5* M 16 Y No U.S.
6 M 12 Y No U.S.
7 M 32 Y No U.S.
8 M 52 N No U.S.
9† M 26 Y No U.S.
10 F 25 Y No U.S.
11 F 30 N No U.S.
12 M 41 N No U.S.
13 M 30 Y No U.S.
14 M 50 Y No U.S.
15 M 44 Y No Italian
16 M 40 Y No Italian
17 F 31 Y No Italian
18 M 34 Y 1 Italian
ote that most but not all subjects with mutations meet full Task Force diagnostic criteria. All sub
nvolvement. *Patients #5 (proband) and #6 are from the same family; †Patients #9 (proband) a
ARVC  arrhythmogenic right ventricular cardiomyopathy; CHF  congestive heart failure; DS
lectrocardiographic; FHx  family history of arrhythmogenic right ventricular cardiomyopathy; ICD
achycardia; NYHA  New York Heart Association functional class; PKP  plakophilin; RVOT  rig
T  ventricular tachycardia.dentified in desmosome-encoding genes other than PKP2. fihe heterozygous mutations identified included 4 variants
n DSP, 5 variants in DSG2, 3 variants in DSC2, and 2
ariants in JUP (Table 4). All variants were identified in
onserved regions, and none of these variants were identi-
ed in 700 ethnic-matched control subjects (1,400
hromosomes).
unctional analysis. Myocardial autopsy samples were
vailable from 2 individuals with PKP2 variants, including 1
atient (PG) with a single heterozygous PKP2 W528X
onsense mutation (no second variant has been identified to
ate) and a second patient (M686) with digenic heterozy-
osity including the PKP2 I531S variant as well as a DSP
207X mutation. These myocardial samples were sec-
ioned and stained for a variety of junctional proteins,
ncluding PKP2, DSP, JUP, N-cadherin, and DSC2/3, as
ell as for Cx43 and DES (Fig. 4). Staining of samples from
atient PG was very weak or absent for each of these
roteins except for DSP, which was normal. In contrast,
taining of samples from patient M686 was essentially
ormal for each antibody, except for Cx43, which was
bsent (Fig. 4), and DSP, which seemed to stain weakly.
hese data suggest that the DSP nonsense mutation in
atient M686 does not affect DSP localization and that
hese variants do not grossly affect the desmosomal junc-
ions. In contrast, both the desmosomal and cadherin
unctions seem to be affected in patient PG, with loss of
taining for N-cadherin and JUP, in addition to PKP2.
ignal intensities were comparable in samples obtained from
oth LV and RV and in areas relatively unaffected by
utationsmal Gene Mutations
tions
Syncope/
SCD
CHF/
NYHA Arrhythmia
ECG
Abnormal
SAECG
Abnormal
No/No No/I VT apex RVOT Yes Yes
Yes/No No/I VT apex RVOT Yes Yes
Yes/No No/I VT RVOT Yes Yes
No/No No/I VT apex Yes Yes
Yes/No No/I VT RVOT Yes Yes
Yes/No No/I VT RVOT Yes Yes
Yes/No No/I VT RVOT apex Yes Yes
No/No No/I VT RVOT Yes Yes
No/No No/I VT RVOT Yes Yes
No/No No/I VT RVOT Yes No
No/No No/I NSVT Yes No
Yes/No No/I VT Yes Yes
Yes/No No/I VT No Yes
Yes/Yes No/I VT-RV origin Yes Yes
Yes/Yes No/I VF Yes Yes
Yes/Yes No/I VF Yes No
No/No No/I NSVT Yes Yes
No/No No/I NSVT Yes Yes
ave right ventricular involvement and arrhythmias, and several subjects also have left ventricular
are from the same family.
esmocollin; DSG  desmoglein; DSP  desmoplakin; DX Criteria  diagnostic criteria; ECG 
lantable cardioverter-defibrillator; M/m major/minor criteria; NSVT  nonsustained ventricular
ricular outflow tract; SAECG  signal-averaged electrocardiogram; SCD  sudden cardiac death;ne Mmoso
alpita
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
jects h
nd #10
C  d
 impbrofatty replacement.
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rrhythmogenic right ventricular cardiomyopathy has
merged as a significant cause of sudden death, heart failure,
nd the need for heart transplantation over the past decade
2,31). The incidence was initially thought to be particularly
igh in the Veneto region of Italy and in other parts of
urope but low elsewhere (2). More recently, the disease
as been increasingly recognized throughout the world
3,32,33). It is believed to be inherited in a moderate
ercentage of cases, with autosomal dominant inheritance
redominating (4). Multiple genes, mostly those encoding
esmosomal proteins, have been identified as causative in
RVC, with PKP2 reported to be responsible for approxi-
ately 25% of all cases (8,18–21). In the work presented
erein, however, interpretation of these data is questioned, and
he concepts of low penetrance as well as compound and
igenic heterozygosity are proposed as potential determinants
f the clinical presentation in subjects carrying mutations and
n their family members. In addition, identification of novel
eterozygous mutations in other desmosome-encoding genes,
ncluding novel mutations in JUP, further supports the notion
hat the “final common pathway” for ARVC is the cell–cell
unctions (34).
In this report, we demonstrate that, whereas variants in
KP2 are relatively common (identified in 38 of 198 or 19%
f probands), harboring 1 PKP2 variant might not by itself
e sufficient to determine overt clinical disease. In at least 16
f 38 (42%) cases, concomitant causes such as either a
ontinuedTable 3 Continued
ICD Transplant
Exercise
VT
RV
Involvement
LV
Involvement
MRI
Abnormal
DX Criteria
M/m Histol
No No No Yes No Yes Yes/Yes Yes
Yes No No Yes No Yes Yes/Yes Yes
Yes No Yes Yes Yes Yes Yes/Yes Yes
No No Yes Yes No Yes Yes/Yes No
Yes No No Yes No Yes Yes/Yes Yes
Yes No No Yes No Yes Yes/Yes Yes
Yes Yes Yes Yes No Yes Yes/Yes Yes
Yes No No Yes Yes Yes Yes/Yes No
Yes No Yes Yes No Yes Yes/Yes Yes
Yes No No Yes No Yes No/Yes Yes
Yes No Yes Yes No Yes No/Yes No
Yes No Yes Yes No Yes Yes/No No
Yes Yes Yes Yes No Yes Yes/No Yes
Yes No Yes Yes No Yes Yes/Yes Yes
Yes No No Yes No Notperformed 1/3 No
Yes No Yes Yes No Yes 1/3 No
No No No Yes Yes Notperformed 1/4 Yes
No No No Yes No Notperformed 1/4 Nosecond hit” in the same gene (compound heterozygosity) or pn a second desmosome-encoding gene (digenic heterozy-
osity) or an acquired disruption of these proteins or
nvironmental factors have been shown to be required for the
vert clinical phenotype to develop or for modification of
isease severity. Hence, whereas PKP2 “mutations” are rela-
ively common, a second variant in PKP2 or in DSP, DSC2,
SG2, PKP4, JUP, or another interacting junction protein-
ncoding gene seems to be important for the disease and its
linical consequences to be manifest. Other “second hit” genes
r interactors are likely to be discovered in the future. In
ddition, a variety of heterozygous mutations in all of the
nown desmosome-encoding genes were identified to cause
RVC and its associated clinical signs and symptoms.
Interestingly, the subjects harboring more than 1 variant
n PKP2 and/or PKP2 plus other desmosome-encoding
enes seem to have earlier onset of disease and more clinical
everity than those individuals harboring heterozygous mu-
ations alone. Interpretation of these data, however, is
onfounded by the small number of large pedigrees available
or analysis. To track segregation of the genotype with
isease, large families with clinical ARVC are required, but
n our study, small families and sporadic cases were pre-
ominantly seen. However, in the families in which multi-
le individuals were enrolled and genetically screened, a
ingle genetic variant commonly did not lead to overt
linical disease with the Task Force criteria (Table 1) or the
tringent diagnostic evaluation used by the ARVD registry.
t will be interesting to determine whether the carriers
Gene Nucleotide Change Amino Acid Change
P2 DSP 1212insT 269AG L404fsX409 Q90R
P2 DSP 1592TG 620GA I531S W207X
P2 DSG2 1592TG 146GA I531S R49H
P2 DSG2 145_148delCAGA 1003AG S50fsX110 T335A
P2 1162CT R388W
P2 2509delA V837fsX930
P2 PKP2 145_148delCAGA 1592TG S50fsX110 I531S
P2 PKP2 1592TG 2359CT I531S L787F
P2 1613GA W538X
C2 1914GC Q63SH
P2 PKP2 DSP 1613GA 1914GC 88GA W538X Q638H V30M
P2 PKP2 DSP 1114GC 2145-1GC 4609CT A372P R1537C
P2 PKP4 2146-1GC 2786AG D929G
P2 PKP2 DSG2 419CT 2146-1GC 166 GA S140F V56M
P2 PKP2 DSG2 627CG 2447_2448delCC 437GA S209R T816fsX825 R146H
P2 PKP2 DSP 630CT 2333TC 3764GA Q211X I778T R1255K
P2 PKP2 DSP 2119CT 184CA 4961TC Q707X Q62K L1654P
P2 DSG2 145_148delCAGA 1115GA S50fsX110 V391Iogy
PK
PK
PK
PK
PK
PK
PK
PK
PK
DS
PK
PK
PK
PK
PK
PK
PK
PKreviously phenotyped as unaffected will be found to have
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chocardiogram, and the like) or whether later development
f clinical signs due to an otherwise concealed pathological
rocess will occur over time. These genetic findings should
ncourage physicians caring for patients with ARVC to
creen as many families as possible, irrespective of clinical
resentation. Clearly, longitudinal follow-up of patients and
arrier family members will be critical in determining the
nfluence of these gene variants and, more importantly, will
e critical in providing excellent preventive care. As noted,
e have only identified second variants in approximately
0% of the probands in whom PKP2 variants were identi-
ed. What about the remainder? Firstly, many genes that
ncode proteins that either directly or indirectly contribute
o the function and integrity of cell adhesion junctions
emain to be screened, such as the genes encoding - or
-catenin. Mutations in proteins of the myocyte cytoarchi-
ecture that are linked to these proteins—such as actin,
-actinin-2, metavinculin, or Z-disk proteins—could be
Figure 3 Pedigree of 2 Italian Families
With Compound Desmosomal Mutations
(A) PKP2 T816fsX825 (diamonds) was identified in the proband and 2 family
members. PKP2 S209R () and DSG2 R146H (club symbol) were also identi-
fied in the proband. (B) PKP2 Q211X (), PKP2 I778T (club symbol), and DSP
R1255K (diamonds) were detected in the proband. All family members carrying
different mutations were completely asymptomatic. The probands are indicated
by the arrows. SD  sudden death; other abbreviations as in Figures 1 and 2.Figure 2 Pedigree of 2 U.S. Families With Compound
Desmosomal Mutations (Digenic Heterozygosity)
(A) PKP2 I531S () was identified in the proband and 2 of her siblings. DSP
W207X (solid diamonds) was identified in the proband who experienced sud-
den death at 25 years of age. Her affected living brother was diagnosed by car-
diac magnetic resonance imaging and is still alive at the age of 42 years. Her
unaffected sister carrying the I531S variant is now 51 years of age and has
twin unaffected daughters, age 19 years, both of whom carry the variant. Indi-
viduals without a definitive diagnosis of arrhythmogenic right ventricular cardio-
myopathy (ARVC) but in whom signs or symptoms compatible with this
diagnosis were reported are identified in blue. The arrow indicates the pro-
band. (B) PKP2 S140F (), PKP2 IVS10-1GC (diamonds) and desmoglein-2
(DSG2) V56M (club symbols) were detected in the proband. The oldest child of
the proband, who is 19 years old, does not meet full Task Force criteria of
ARVC but has arrhythmias and symptoms. The arrow indicates the proband.
ABN Echo  abnormal echocardiogram; CHF  congestive heart failure; PM 
pacemaker; SD  sudden death; other abbreviations as in Figure 1.
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ions could result in dominant negative proteins giving rise
o autosomal dominant inheritance, the mode of inheritance
idely held as the most common in patients suffering from
RVC. In addition to the compound heterozygous and
igenic mutations noted, we also identified apparent iso-
ated heterozygous mutations in desmosome-encoding
enes in another 7% of subjects. We would speculate that
ther relevant genes have yet to be discovered. An interest-
ng observation from these studies is that nonsense or
rame-shift mutations alone in PKP2 often do not result in
linical disease in these families. These data would suggest
hat haploinsufficiency for PKP2 is not critically important
Figure 4
Immunostaining of Myocardial Sections From a Control
Heart and From the Hearts of ARVC Patients PG (PKP2
W538X) and M686 (PKP2 I531S and DSP W207X)
The panels show staining for PKP2 (top), DSP (middle), and connexin
43 (bottom). Bars  20 m. Abbreviations as in Figures 1 and 2.
Heterozygous Mutations Identified in DesmosomTable 4 Heterozygous Mutations Identified i
Patient # Sex Gene
1 M DSC2
2 M DSC2
3 F DSC2
4 M DSG2
5 M DSG2
6 M DSG2
7 M DSG2
8 F DSG2
9 M DSP
10 F DSP
11 M DSP
12 F DSP
13 M JUP
14 M JUP
JUP  junctional plakoglobin; other abbreviations as in Tables 2 anddr even sufficient or that compensatory mechanisms occur.
nly when the remaining copy of PKP2 is mutated or there
s a mutation in another gene does overt clinical disease
evelop. It also suggests that the description of these genetic
ariants as “disease-causing mutations” might be inaccurate
nd that defining affectation status by genetic analysis alone
ight not be entirely appropriate. For instance, on face
alue, the I531S variant would seem to be a polymorphism.
owever, the detection of this variant in 5 of the 143
robands (from different regions of the U.S.) but in none of
he 700 control subjects would suggest that this variant is
inked to disease. In contrast, nonsense mutations in PKP2
ould be expected to result in overt clinical disease but, in
any cases, does not. For this reason, we would caution
otential “fee-for-service” laboratories offering “clinical test-
ng” for ARVC from definitive statements regarding cause-
nd-effect relationships, particularly in subjects in whom
KP2 variants are identified, especially if the remaining
enes are not screened. In this circumstance, not only is the
ffected subject at risk to have a mistaken causative gene
ssigned but “at-risk” family members might be either
istakenly diagnosed with a causative mutation or, more
oncerning, be given a negative result. In the latter case, this
ould lead to discharge from follow-up despite actually
arrying a disease-causing mutation in another gene not
nalyzed. This could lead to tragic outcomes. Grossmann
t al. (35) ablated the PKP2 gene in mice, causing lethal
lteration in heart morphogenesis at mid-gestation charac-
erization by reduced trabeculations, disarrayed cytoskele-
on, rupture of the cardiac wall, and hemopericardium. In
he absence of PKP2, the cytoskeletal linker protein desmo-
lakin dissociates from the junctional plaques that connect
ardiomyocytes, resulting in reduced architectural stability
f intercalated disks. Constant mechanical stress, as seen in
he contracting heart, is likely to be deleterious to the
eakened intercellular junctions, leading to disruption,
nes Other Than PKP2smosomal Genes Other Than PKP2
Nucleotide Change Amino Acid Change
874 CT P292S
1026 AG I342V
1660 CT Q554X
146 GA R49H
560 AG D187G
1520 GA C507Y
1003 AG T335A
961 TA F321I
8501 GA R2834H
1598 TC I533T
688 GA D230N
1482 AT Y494F
392_394delTCA I31delI
475 GT V159Lal Gen Deilation, and dysfunction. However, heterozygous mice
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hat haploinsufficiency for PKP2 is not sufficient to cause
isease. The RV—on the basis of its geometry, architecture,
nd role in cardiac function—dilates to a variety of volume
nd pressure abnormalities and would likely develop struc-
ural and functional disease earlier than the LV. This was
learly shown in the DSP transgenic mouse model of Yang
t al. (29), who demonstrated early RV dilation with later
V dilation as well as intercalated disk disruption and loss
f desmosomes. In addition, further support is provided by
he fact that the LV develops late-onset disease in some
atients with ARVC (3,36). In addition to the genetic
utations, mechanical stress and stretch forces on the
isturbed desmosome and intercalated disk likely play a role
n disease development and severity (34,37).
tudy limitations. The lack of functional studies of the
ariants described is a limitation of the study. Cellular and
nimal models incorporating these mutations individually
nd together could help to resolve these issues to some
xtent, but these approaches might not necessarily recapit-
late the human condition. In an attempt to better under-
tand the mechanisms involved in the development (or lack
f development) of the clinical phenotype associated with
hese variants, we are in the process of developing these
odels for study. In addition to the models, the addition of
echanical stretch and stress on the cells and animals could
acilitate the development of phenotypic differences from
onstressed models and provide greater insight.
onclusions
ogether, the genetic and functional data provided here
hould help to define the nature of the genetic and clinical
asis of ARVC. This work could significantly impact on
linical genetic screening, because simple single gene anal-
sis (particularly for PKP2) would be inappropriate, and the
otential for inaccurate interpretation based on single (or
ven multiple) gene analysis seems to be high. More
etailed information regarding the true clinical relevance of
KP2 mutations is needed. Furthermore, the moderate
umber of mutations in the other desmosome-encoding
enes strongly suggests that all genes in this pathway should
e screened in all subjects. Identification of heterozygous
utations in JUP as well as the potential mutation within
he PKP4 gene adds to the spectrum of affected genes
nvolving the desmosome. Further studies of PKP4 in
ubjects with ARVC as well as functional analysis of models
ith mutant PKP4 will be needed to clearly state that this is
potential disease-causing gene in ARVC.
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